Development of new therapy using EBV episomal vector in model mouse of EBV infectious diseases
| Project/Area Number |
15K06819
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory animal science
|
|---|
| Research Institution | National Center for Child Health and Development |
|---|
Principal Investigator |
Matsuda Go 国立研究開発法人国立成育医療研究センター, 高度先進医療研究室, 研究員 (60392130)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | トランスレーショナルリサーチ / ウイルス / 感染症 / 癌 / ゲノム |
|---|
| Outline of Final Research Achievements |
Epstein-Barr virus (EBV) is associated with various neoplastic diseases. The development of new therapy is desired because there is not a specific cure for EBV. The aim of this study is to develop the therapy which induce apoptosis to specific infected cells with EBV episomal vector and Herpesvirus TK-GCV therapy in model mouse of EBV disease.
In this research, at the culture cell level we showed that the inhibitory effect of EBV was enough but the effect was not observed in the mice because decreasing the expression level of TK. However, the new therapy may be developed by increasing the expression level of TK.
|
Report
(4 results)
Research Products
(7 results)
